Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
Purpose We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia. Methods We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero. Results We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference − 4.3%; 99% confidence interval (CI) − 11.7–3.0; relative risk 0.89; 0.72–1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI − 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (− 3 to 10; P = 0.22). Conclusion Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Intensive care medicine - 48(2022), 5 vom: 31. März, Seite 580-589 |
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
© Springer-Verlag GmbH Germany, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s00134-022-06677-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR046861947 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR046861947 | ||
| 003 | DE-627 | ||
| 005 | 20230519235249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220429s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00134-022-06677-2 |2 doi | |
| 035 | |a (DE-627)SPR046861947 | ||
| 035 | |a (SPR)s00134-022-06677-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Granholm, Anders |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer-Verlag GmbH Germany, part of Springer Nature 2022 | ||
| 520 | |a Purpose We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia. Methods We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero. Results We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference − 4.3%; 99% confidence interval (CI) − 11.7–3.0; relative risk 0.89; 0.72–1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI − 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (− 3 to 10; P = 0.22). Conclusion Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hypoxaemia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Critical illness |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Corticosteroids |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Quality of life |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mortality |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kjær, Maj-Brit Nørregaard |4 aut | |
| 700 | 1 | |a Munch, Marie Warrer |4 aut | |
| 700 | 1 | |a Myatra, Sheila Nainan |4 aut | |
| 700 | 1 | |a Vijayaraghavan, Bharath Kumar Tirupakuzhi |4 aut | |
| 700 | 1 | |a Cronhjort, Maria |4 aut | |
| 700 | 1 | |a Wahlin, Rebecka Rubenson |4 aut | |
| 700 | 1 | |a Jakob, Stephan M. |4 aut | |
| 700 | 1 | |a Cioccari, Luca |4 aut | |
| 700 | 1 | |a Vesterlund, Gitte Kingo |4 aut | |
| 700 | 1 | |a Meyhoff, Tine Sylvest |4 aut | |
| 700 | 1 | |a Helleberg, Marie |4 aut | |
| 700 | 1 | |a Møller, Morten Hylander |4 aut | |
| 700 | 1 | |a Benfield, Thomas |4 aut | |
| 700 | 1 | |a Venkatesh, Balasubramanian |4 aut | |
| 700 | 1 | |a Hammond, Naomi E. |4 aut | |
| 700 | 1 | |a Micallef, Sharon |4 aut | |
| 700 | 1 | |a Bassi, Abhinav |4 aut | |
| 700 | 1 | |a John, Oommen |4 aut | |
| 700 | 1 | |a Jha, Vivekanand |4 aut | |
| 700 | 1 | |a Kristiansen, Klaus Tjelle |4 aut | |
| 700 | 1 | |a Ulrik, Charlotte Suppli |4 aut | |
| 700 | 1 | |a Jørgensen, Vibeke Lind |4 aut | |
| 700 | 1 | |a Smitt, Margit |4 aut | |
| 700 | 1 | |a Bestle, Morten H. |4 aut | |
| 700 | 1 | |a Andreasen, Anne Sofie |4 aut | |
| 700 | 1 | |a Poulsen, Lone Musaeus |4 aut | |
| 700 | 1 | |a Rasmussen, Bodil Steen |4 aut | |
| 700 | 1 | |a Brøchner, Anne Craveiro |4 aut | |
| 700 | 1 | |a Strøm, Thomas |4 aut | |
| 700 | 1 | |a Møller, Anders |4 aut | |
| 700 | 1 | |a Khan, Mohd Saif |4 aut | |
| 700 | 1 | |a Padmanaban, Ajay |4 aut | |
| 700 | 1 | |a Divatia, Jigeeshu Vasishtha |4 aut | |
| 700 | 1 | |a Saseedharan, Sanjith |4 aut | |
| 700 | 1 | |a Borawake, Kapil |4 aut | |
| 700 | 1 | |a Kapadia, Farhad |4 aut | |
| 700 | 1 | |a Dixit, Subhal |4 aut | |
| 700 | 1 | |a Chawla, Rajesh |4 aut | |
| 700 | 1 | |a Shukla, Urvi |4 aut | |
| 700 | 1 | |a Amin, Pravin |4 aut | |
| 700 | 1 | |a Chew, Michelle S. |4 aut | |
| 700 | 1 | |a Wamberg, Christian Aage |4 aut | |
| 700 | 1 | |a Bose, Neeta |4 aut | |
| 700 | 1 | |a Shah, Mehul S. |4 aut | |
| 700 | 1 | |a Darfelt, Iben S. |4 aut | |
| 700 | 1 | |a Gluud, Christian |4 aut | |
| 700 | 1 | |a Lange, Theis |4 aut | |
| 700 | 1 | |a Perner, Anders |0 (orcid)0000-0002-4668-0123 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Intensive care medicine |d Berlin : Springer, 1975 |g 48(2022), 5 vom: 31. März, Seite 580-589 |w (DE-627)SPR001167375 |w (DE-600)1459201-0 |x 1432-1238 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2022 |g number:5 |g day:31 |g month:03 |g pages:580-589 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00134-022-06677-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2022 |e 5 |b 31 |c 03 |h 580-589 | ||